Trials / Recruiting
RecruitingNCT06643754
A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
A Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-3276 Injection in Patients With Advanced Malignant Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 115 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3276 for injection in patients with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-3276 | Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset. Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage. Indication Expansion: Indications will be selected to evaluate preliminary efficacy. |
Timeline
- Start date
- 2024-12-10
- Primary completion
- 2027-12-30
- Completion
- 2028-12-30
- First posted
- 2024-10-16
- Last updated
- 2025-01-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06643754. Inclusion in this directory is not an endorsement.